Veracyte VCYT Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $88.01M+32.6% | $66.35M+119% | $30.32M+15.1% | $26.34M-20.3% | $33.05M+36.9% | ||
| $21.48M+0.3% | $21.42M-4.3% | $22.37M-2.7% | $22.98M-1.1% | $23.23M-1.0% | ||
| $45.4M+4.1% | $43.6M+3.0% | $42.33M+5.0% | $40.32M+2.9% | $39.19M+8.1% | ||
| —— | —— | —— | -$149K+13.4% | -$172K+14.9% | ||
| —— | —— | —— | —— | —— | ||
| -$5.57M-436% | -$1.04M+45.4% | -$1.9M-470% | $514K-88.2% | $4.36M+201% | ||
| -$271K+48.4% | -$525K— | —— | —— | —— | ||
| -$2.22M+10.4% | -$2.48M-108% | $31.52M+3.2% | $30.53M+2.6% | $29.75M+1.6% | ||
| -$13.86M+10.4% | -$15.46M-691% | -$1.95M-24.1% | -$1.58M-857% | $208K-90.4% | ||
| $166.16M+21.9% | $136.31M+25.9% | $108.25M+15.8% | $93.45M+4.5% | $89.42M+19.1% | ||
| $10.82M+11.8% | $9.68M-3.6% | $10.04M+5.8% | $9.49M-13.5% | $10.97M-2.8% | ||
| $225M+50.0% | $150M0.0% | $150M0.0% | $150M+50.0% | $100M+100.0% | ||
| —— | —— | —— | -$108.43M+2.3% | -$110.97M-97.2% | ||
| $13.85M-1.6% | $14.08M+1.8% | $13.84M-32.6% | $20.51M+2.6% | $19.99M0.0% | ||
| $18.22M-0.5% | $18.3M+2.1% | $17.92M+3.7% | $17.29M+6.6% | $16.21M+53.1% | ||
| —— | —— | —— | —— | —— | ||
| $587K-18.4% | $719K+135% | $306K— | —— | —— | ||
| $77.03M-37.7% | $123.6M— | —— | —— | —— | ||
| —— | —— | $3.42M-9.4% | $3.77M+60.0% | $2.36M+5.4% | ||
| —— | —— | —— | —— | —— | ||
| -$13.86M+10.4% | -$15.46M-691% | -$1.95M-24.1% | -$1.58M-857% | $208K-90.4% | ||
| —— | —— | —— | $3.84M+3,325% | $112K+105% | ||
| —— | —— | —— | —— | $4M+2.7% | ||
| —— | —— | —— | —— | —— | ||
| -$2.22M+10.4% | -$2.48M-108% | $31.52M+3.2% | $30.53M+2.6% | $29.75M+1.6% | ||
| —— | —— | $7.86M+71.9% | $4.57M— | —— | ||
| $2.82M-5.8% | $2.99M-17.3% | $3.62M-15.3% | $4.27M-9.6% | $4.72M-4.7% | ||
| -$606K-4.3% | -$581K-127% | -$256K-40.7% | -$182K-85.7% | -$98K+57.9% | ||
| $225M+50.0% | $150M0.0% | $150M0.0% | $150M+50.0% | $100M+100.0% | ||
| —— | —— | —— | —— | —— | ||
| —— | $2.85M+33.3% | $2.13M+50.0% | $1.42M+100% | $711.25K— | ||
| -$2.22M+10.4% | -$2.48M-108% | $31.52M+3.2% | $30.53M+2.6% | $29.75M+1.6% | ||
| —— | $0-100% | $1.13M-50.0% | $2.25M-33.3% | $3.38M-25.0% | ||
| $155.34M+22.7% | $126.63M+28.9% | $98.21M+17.0% | $83.97M+7.0% | $78.45M+22.9% | ||
| $155.34M+22.7% | $126.63M+28.9% | $98.21M+17.0% | $83.97M+7.0% | $78.45M+22.9% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Veracyte's cash flow data come from?
- Every line is extracted from Veracyte's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.